In a new study, clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) have demonstrated the use of exosomes to successfully target squamous cell cancer tumours that are usually resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Their research is the first where exosomes have been applied to target TKI-resistant cancers in Singapore. The findings were published in the journal Developmental Cell last month.
SEC fines former Merck exec over insider trading allegations
The Securities and Exchange Commission said a former Merck executive agreed to pay $82,000 after alleging he purchased shares of a company right before it was acquired by the drugmaker. Nirdosh